Cancer clinical trials in the region Île-de-France

787 currently recruiting clinical trials
Region Île-de-France
Phase 1 / Phase 2 Lung cancer #NCT06892548 #2024-520238-31-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
ALK BRAF EGFR HER2 KRAS G12C MET NTRK-1/2/3 RET ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2 Lung cancer #NCT06892548 #2024-520238-31-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK BRAF EGFR HER2 KRAS G12C MET NTRK-1/2/3 RET ROS-1
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2 Lung cancer #NCT06892548 #2024-520238-31-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2 Lung cancer #NCT06892548 #2024-520238-31-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2 Lung cancer #NCT06772623 #2024-514465-18-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK BRAF EGFR HER2 HRAS KRAS G12C KRAS non G12C MET NTRK-1/2/3 RET ROS-1
7 recruiting sites
Abbvie
Phase 1 / Phase 2 Acute leukemia #NCT04988555 #2022-502741-10-00
Required histologic types
Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML) Other acute leukemia
Required central nervous system lesions
None Treated / Controled
Required renal function statuses
> 60 ml/min 50-60 ml/min
Required genetic anomalies
KMT2A MLL fusions NPM1
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Lymphoma #NCT06564038 #2024-515034-33-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II) Disseminated (stage III and IV)
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
AstraZeneca
Phase 1 / Phase 2 Lymphoma #NCT06564038 #2024-515034-33-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required number of previous lines of therapy
None
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2 Lymphoma #NCT06564038 #2024-515034-33-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma Follicular lymphoma Marginal zone lymphoma MALT lymphoma Lymphocytic lymphoma Indolent transformed lymphoma
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2 Lymphoma CLL & Richter's syndrome #NCT06564038 #2024-515034-33-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca